{"id":"https://openalex.org/W4293222009","doi":"https://doi.org/10.1038/s41416-022-01926-z","title":"Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE","display_name":"Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE","publication_year":2022,"publication_date":"2022-08-25","ids":{"openalex":"https://openalex.org/W4293222009","doi":"https://doi.org/10.1038/s41416-022-01926-z","pmid":"https://pubmed.ncbi.nlm.nih.gov/36008705","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9596492"},"language":"en","primary_location":{"id":"doi:10.1038/s41416-022-01926-z","doi":"https://doi.org/10.1038/s41416-022-01926-z","is_oa":false,"landing_page_url":"https://doi.org/10.1038/s41416-022-01926-z","pdf_url":null,"source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9596492/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039790911","display_name":"Geoffrey Alan Watson","orcid":"https://orcid.org/0000-0003-1962-7893","observed_orcids":["https://orcid.org/0000-0003-1962-7893"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Geoffrey A. Watson","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":"https://orcid.org/0000-0003-1962-7893","affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065153048","display_name":"Zachary William Neil Veitch","orcid":"https://orcid.org/0000-0002-3223-5045","observed_orcids":["https://orcid.org/0000-0002-3223-5045"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Zachary W. Veitch","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036010865","display_name":"Daniel Shepshelovich","orcid":"https://orcid.org/0000-0002-9145-618X","observed_orcids":["https://orcid.org/0000-0002-9145-618X"]},"institutions":[{"id":"https://openalex.org/I16391192","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49","country_code":"IL","type":"education","lineage":["https://openalex.org/I16391192"]},{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA","IL"],"is_corresponding":false,"raw_author_name":"Daniel Shepshelovich","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","Medicine D, Tel-Aviv Medical Center, and the Sackler School of Medicine, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Medicine D, Tel-Aviv Medical Center, and the Sackler School of Medicine, Tel Aviv, Israel","institution_ids":["https://openalex.org/I16391192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024148150","display_name":"Zhihui Amy Liu","orcid":"https://orcid.org/0000-0003-1537-4868","observed_orcids":["https://orcid.org/0000-0003-1537-4868"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Zhihui Amy Liu","raw_affiliation_strings":["Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088186975","display_name":"Anna Spreafico","orcid":"https://orcid.org/0000-0002-3034-3042","observed_orcids":["https://orcid.org/0000-0002-3034-3042"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Anna Spreafico","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":"https://orcid.org/0000-0002-3034-3042","affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112795141","display_name":"Albiruni R. Abdul Razak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Albiruni R. Abdul Razak","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041145711","display_name":"Philippe Lucien Bedard","orcid":"https://orcid.org/0000-0002-6771-2999","observed_orcids":["https://orcid.org/0000-0002-6771-2999"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Philippe L. Bedard","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000204204","display_name":"Lillian L. Siu","orcid":"https://orcid.org/0000-0002-3500-0540","observed_orcids":["https://orcid.org/0000-0002-3500-0540"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Lillian L. Siu","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":"https://orcid.org/0000-0002-3500-0540","affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037416583","display_name":"Lori M. Minasian","orcid":"https://orcid.org/0000-0002-0472-4079","observed_orcids":["https://orcid.org/0000-0002-0472-4079"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lori Minasian","raw_affiliation_strings":["National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Institute, National Institutes of Health, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022267545","display_name":"Aaron Richard Hansen","orcid":"https://orcid.org/0000-0002-2363-8707","observed_orcids":["https://orcid.org/0000-0002-2363-8707"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Aaron R. Hansen","raw_affiliation_strings":["Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. aaron.hansen@uhn.ca","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"],"raw_orcid":"https://orcid.org/0000-0002-2363-8707","affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. aaron.hansen@uhn.ca","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5022267545"],"corresponding_institution_ids":["https://openalex.org/I2802654988"],"apc_list":{"value":4480,"currency":"USD","value_usd":4480},"apc_paid":null,"fwci":1.4583,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.82954709,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"127","issue":"9","first_page":"1629","last_page":"1635"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.6528000235557556,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.6528000235557556,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.2020999938249588,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.07900000363588333,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pro-ctcae","display_name":"PRO-CTCAE","score":0.9139999747276306},{"id":"https://openalex.org/keywords/adverse-event-reporting","display_name":"adverse event reporting","score":0.7680000066757202},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.8040000200271606},{"id":"https://openalex.org/keywords/symptom-severity","display_name":"symptom severity","score":0.5619999766349792},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.7670000195503235},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9760000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6578913927078247},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6460791230201721},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5624156594276428},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.44089144468307495},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.35036301612854004},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3425270915031433},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19433394074440002},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000071066","descriptor_name":"Patient Reported Outcome Measures","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008495","descriptor_name":"Medical Oncology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D035703","descriptor_name":"Therapies, Investigational","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1038/s41416-022-01926-z","doi":"https://doi.org/10.1038/s41416-022-01926-z","is_oa":false,"landing_page_url":"https://doi.org/10.1038/s41416-022-01926-z","pdf_url":null,"source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmid:36008705","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36008705","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:9596492","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9596492/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:9596492","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9596492/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1508560016","https://openalex.org/W1842042263","https://openalex.org/W1971685703","https://openalex.org/W2113464761","https://openalex.org/W2124458984","https://openalex.org/W2131076472","https://openalex.org/W2165690041","https://openalex.org/W2168921218","https://openalex.org/W2284281005","https://openalex.org/W2314226163","https://openalex.org/W2413118791","https://openalex.org/W2588457571","https://openalex.org/W2767833895","https://openalex.org/W2917197653","https://openalex.org/W2944801570","https://openalex.org/W2998727000","https://openalex.org/W3007702378","https://openalex.org/W3049238914","https://openalex.org/W3088449328","https://openalex.org/W3110120874","https://openalex.org/W3131746895"],"related_works":["https://openalex.org/W3171043130","https://openalex.org/W3031787110","https://openalex.org/W2597543786","https://openalex.org/W4310807091","https://openalex.org/W2977939617","https://openalex.org/W3131746895","https://openalex.org/W4405043927","https://openalex.org/W7223453658","https://openalex.org/W3130482401","https://openalex.org/W2413118791"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2022-08-27T00:00:00"}